235 related articles for article (PubMed ID: 3677513)
1. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE
Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
[TBL] [Abstract][Full Text] [Related]
2. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women.
Need AG; Horowitz M; Bridges A; Morris HA; Nordin BE
Arch Intern Med; 1989 Jan; 149(1):57-60. PubMed ID: 2912415
[TBL] [Abstract][Full Text] [Related]
3. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis.
Need AG; Horowitz M; Walker CJ; Chatterton BE; Chapman IC; Nordin BE
Bone; 1989; 10(1):3-6. PubMed ID: 2736154
[TBL] [Abstract][Full Text] [Related]
4. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
Gennari C; Agnusdei D; Gonnelli S
Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
[TBL] [Abstract][Full Text] [Related]
5. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
Johansen JS; Hassager C; Pødenphant J; Riis BJ; Hartwell D; Thomsen K; Christiansen C
Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884
[TBL] [Abstract][Full Text] [Related]
6. Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate.
Erdtsieck RJ; Pols HA; van Kuijk C; Birkenhäger-Frenkel DH; Zeelenberg J; Kooy PP; Mulder P; Birkenhäger JC
J Bone Miner Res; 1994 Feb; 9(2):277-83. PubMed ID: 8140941
[TBL] [Abstract][Full Text] [Related]
7. Anabolic steroids in corticosteroid-induced osteoporosis.
Adami S; Rossini M
Wien Med Wochenschr; 1993; 143(14-15):395-7. PubMed ID: 8256456
[TBL] [Abstract][Full Text] [Related]
8. Effect of calcitonin or the anabolic steroid Decadurabolin on serum beta 2 microglobulin in osteoporotic postmenopausal women.
Cantatore FP; Loperfido MC; Mancini L; Carrozzo M
J Rheumatol; 1992 Nov; 19(11):1753-5. PubMed ID: 1491396
[TBL] [Abstract][Full Text] [Related]
9. Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women.
Need AG; Morris HA; Hartley TF; Horowitz M; Nordin BE
Calcif Tissue Int; 1987 Jul; 41(1):7-10. PubMed ID: 3113703
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
Geusens P; Dequeker J
Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
[TBL] [Abstract][Full Text] [Related]
11. Total and local bone mineral during estrogen treatment: a placebo controlled trial.
Gotfredsen A; Riis BJ; Christiansen C
Bone Miner; 1986 Apr; 1(2):167-73. PubMed ID: 3334206
[TBL] [Abstract][Full Text] [Related]
12. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
Bolanca S; Korsić M; Dekanić D; Cvijetić S
Acta Med Croatica; 1998; 52(3):159-63. PubMed ID: 9818438
[TBL] [Abstract][Full Text] [Related]
13. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
Flicker L; Hopper JL; Larkins RG; Lichtenstein M; Buirski G; Wark JD
Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
[TBL] [Abstract][Full Text] [Related]
14. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study.
Gennari C; AgnusDei D; Gonnelli S; Nardi P
Maturitas; 1989 Sep; 11(3):187-97. PubMed ID: 2687645
[TBL] [Abstract][Full Text] [Related]
15. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.
Hassager C; Jensen LT; Pødenphant J; Thomsen K; Christiansen C
Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, biochemistry and some results with treatment of postmenopausal osteoporosis.
Hassager C; Christiansen C
Wien Med Wochenschr; 1993; 143(14-15):389-91. PubMed ID: 8256454
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
Geusens P; Dequeker J; Verstraeten A; Nijs J; Van Holsbeeck M
Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
[TBL] [Abstract][Full Text] [Related]
18. [Effects of nandrolone decanoate on bone mineral content and intestinal absorption of calcium].
Nuti R; Righi GA; Turchetti V; Vattimo A
Minerva Med; 1984 Jan; 75(3-4):109-13. PubMed ID: 6366617
[TBL] [Abstract][Full Text] [Related]
19. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
Mulligan K; Zackin R; Clark RA; Alston-Smith B; Liu T; Sattler FR; Delvers TB; Currier JS; ;
Arch Intern Med; 2005 Mar; 165(5):578-85. PubMed ID: 15767536
[TBL] [Abstract][Full Text] [Related]
20. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.
Geusens P
Clin Rheumatol; 1995 Sep; 14 Suppl 3():32-9. PubMed ID: 8846659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
